5-ALA fluorescence for intraoperative visualization of spinal ependymal tumors and identification of unexpected residual tumor tissue: experience in 31 patients.

5-ALA 5-aminolevulinic acid fluorescence oncology residual fluorescing tumor spinal ependymal tumors

Journal

Journal of neurosurgery. Spine
ISSN: 1547-5646
Titre abrégé: J Neurosurg Spine
Pays: United States
ID NLM: 101223545

Informations de publication

Date de publication:
04 Dec 2020
Historique:
received: 05 04 2020
accepted: 29 06 2020
medline: 5 12 2020
pubmed: 5 12 2020
entrez: 4 12 2020
Statut: epublish

Résumé

Gross-total resection (GTR) is the treatment of choice in the majority of patients suffering from spinal ependymal tumors. In such tumors, the extent of resection (EOR) is considered the key factor for tumor recurrence and thus patient prognosis. However, incomplete resection is not uncommon and leads to increased risk of tumor recurrence. One important cause of incomplete resection is insufficient intraoperative visualization of tumor tissue as well as residual tumor tissue. Therefore, the authors investigated the value of 5-aminolevulinic acid (5-ALA)-induced fluorescence in a series of spinal ependymal tumors for improved tumor visualization. Adult patients who underwent preoperative 5-ALA administration and surgery for a spinal ependymal tumor were included in this study. For each tumor, a conventional white-light microsurgical resection was performed. Additionally, the fluorescence status (strong, vague, or no fluorescence) and fluorescence homogeneity (homogenous or inhomogeneous) of the spinal ependymal tumors were evaluated during surgery using a modified neurosurgical microscope. In intramedullary tumor cases with assumed GTR, the resection cavity was investigated for potential residual fluorescing foci under white-light microscopy. In cases with residual fluorescing foci, these areas were safely resected and the corresponding samples were histopathologically screened for the presence of tumor tissue. In total, 31 spinal ependymal tumors, including 27 intramedullary tumors and 4 intradural extramedullary tumors, were included in this study. Visible fluorescence was observed in the majority of spinal ependymal tumors (n = 25, 81%). Of those, strong fluorescence was noted in 23 of these cases (92%), whereas vague fluorescence was present in 2 cases (8%). In contrast, no fluorescence was observed in the remaining 6 tumors (19%). Most ependymal tumors demonstrated an inhomogeneous fluorescence effect (17 of 25 cases, 68%). After assumed GTR in intramedullary tumors (n = 15), unexpected residual fluorescing foci within the resection cavity could be detected in 5 tumors (33%). These residual fluorescing foci histopathologically corresponded to residual tumor tissue in all cases. This study indicates that 5-ALA fluorescence makes it possible to visualize the majority of spinal ependymal tumors during surgery. Unexpected residual tumor tissue could be detected with the assistance of 5-ALA fluorescence in approximately one-third of analyzed intramedullary tumors. Thus, 5-ALA fluorescence might be useful to increase the EOR, particularly in intramedullary ependymal tumors, in order to reduce the risk of tumor recurrence.

Identifiants

pubmed: 33276339
doi: 10.3171/2020.6.SPINE20506
pii: 2020.6.SPINE20506
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

374-382

Auteurs

Matthias Millesi (M)

1Department of Neurosurgery.
4Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Austria.

Barbara Kiesel (B)

1Department of Neurosurgery.
4Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Austria.

Vanessa Mazanec (V)

1Department of Neurosurgery.
4Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Austria.

Lisa I Wadiura (LI)

1Department of Neurosurgery.
4Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Austria.

Adelheid Wöhrer (A)

2Division of Neuropathology and Neurochemistry, Department of Neurology.
4Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Austria.

Johannes Herta (J)

1Department of Neurosurgery.

Stefan Wolfsberger (S)

1Department of Neurosurgery.
4Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Austria.

Klaus Novak (K)

1Department of Neurosurgery.

Julia Furtner (J)

3Department of Biomedical Imaging and Image-Guided Therapy; and.
4Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Austria.

Karl Rössler (K)

1Department of Neurosurgery.
4Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Austria.

Engelbert Knosp (E)

1Department of Neurosurgery.
4Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Austria.

Georg Widhalm (G)

1Department of Neurosurgery.
4Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Austria.

Classifications MeSH